title: [Multiple myeloma].
abstract: Multiple myeloma is the second most common hematological malignancy. It is defined by the presence of monoclonal plasma cells capable to produce a monoclonal paraprotein causing clinical abnormalities such as anemia, renal insufficiency, hypercalcemia, or bone lesions. New chromosomal or molecular abnormalities have been identified allowing a better management. Multiple myeloma is treatable and, although it remains incurable, the patient prognosis and quality of life has notably improved, so it is not rare to see series with a median survival longer than 5 years. Even more, it is possible by now to expect improvements respect to the standard autologous stem cell transplantation. This must be attributed to the emergence of a number of new therapies entering clinical practice over the last 6 years: thalidomide (Thalidomid Pharmion, Boulder, CO, USA), lenalidomide (Revlimid, Celgene Corporation, Summit, NJ, USA) and bortezomib (Velcade, Janssen Pharmaceutica N.V., Belgium). Finally, we also will review the current clinical experience in supportive therapy, which has also contributed to the patient outcome improvement with approaches such as: new indications for dialysis, use of erythropoietin receptor stimulating agents and bisphosphonates, and new surgical therapies such as vertebroplastia and kyphoplastia.
authors.affiliation: Servicio de Hematología, Hospital Universitario de Salamanca, Centro de Investigación del Cáncer, Salamanca, España. rgarcias@usal.es
authors.forename: Ramón
authors.initials: R
authors.lastname: García-Sanz
authors.forename: María Victoria
authors.initials: MV
authors.lastname: Mateos
authors.forename: Jesús Fernando
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D009101:Multiple Myeloma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011379:Prognosis